Bellerophon Therapeutics
Presencia
Bellerophon Therapeutics es una empresa que cotiza bajo el símbolo de cotización BLPH (US).
Ejecutivos
Ver el organigrama con sus 5 ejecutivos principales
Biografías más buscadas en Bellerophon Therapeutics
- Peter Fernandes, Chief Executive Officer
- Scott Bruder, Director
- Mary Ann Cloyd, Independent Director
Crear su alerta
para seguir los movimientos de los ejecutivos en Bellerophon Therapeutics.
Biotecnología
Bellerophon Therapeutics tiene 2.282 competidores entre los que se incluyen Lonza (Suiza), Eurofins (Luxemburgo) y Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnología
- Endeavor BioMedicines acaba de anunciar una recaudación de fondos de 132 millones de dólares. (publicado el 25 de abril de 2024).
- Metsera acaba de anunciar una recaudación de fondos de 290 millones de dólares. (publicado el 23 de abril de 2024).
- Histogen has filed for bankruptcy protection (publicado el 19 de abril de 2024).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Bellerophon Therapeutics
- Press Releases | Bellerophon Therapeutics, Inc.
- Bellerophon Announces Positive Top-line Results from Cohort 2 of Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease | Bellerophon Therapeutics, Inc.
- Bellerophon Announces Positive Initial Data from Acute Hemodynamic Dose Escalation Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease | Bellerophon Therapeutics, Inc.
- Bellerophon Presents New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at Pulmonary Fibrosis Foundation Summit 2019 | Bellerophon Therapeutics, Inc.
- Bellerophon Provides Business Update and Reports Third Quarter 2019 Financial Results | Bellerophon Therapeutics, Inc.
- Bellerophon Presents New Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019 Annual Meeting | Bellerophon Therapeutics, Inc.
- Bellerophon to Present New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019 Annual Meeting | Bellerophon Therapeutics, Inc.
- Bellerophon Receives Orphan Drug Designation for Nitric Oxide in the Treatment of Idiopathic Pulmonary Fibrosis | Bellerophon Therapeutics, Inc.
- Bellerophon to Present at the H.C. Wainwright 21st Annual Global Investment Conference | Bellerophon Therapeutics, Inc.
- View more press releases Close
Redes sociales sobre Bellerophon Therapeutics
- Bellerophon Therapeutics en Wikipedia, Google News y Yahoo Finance
- Bellerophon Therapeutics en LinkedIn, Twitter y YouTube
Ponerse en contacto
Contactar a través de e-mail con sus ejecutivos Peter Fernandes 
Llame a Bellerophon Therapeutics al +1 908...
